Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Revenue (2017 - 2026)

Organogenesis Holdings has reported Revenue over the past 9 years, most recently at $225.6 million for Q4 2025.

  • For Q4 2025, Revenue rose 78.13% year-over-year to $225.6 million; the TTM value through Dec 2025 reached $564.2 million, up 17.04%, while the annual FY2025 figure was $564.2 million, 17.04% up from the prior year.
  • Revenue for Q4 2025 was $225.6 million at Organogenesis Holdings, up from $150.9 million in the prior quarter.
  • Over five years, Revenue peaked at $225.6 million in Q4 2025 and troughed at $86.7 million in Q1 2025.
  • A 5-year average of $119.9 million and a median of $115.3 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: soared 78.65% in 2021 and later decreased 22.44% in 2025.
  • Year by year, Revenue stood at $127.9 million in 2021, then dropped by 9.65% to $115.5 million in 2022, then fell by 13.73% to $99.7 million in 2023, then grew by 27.1% to $126.7 million in 2024, then soared by 78.13% to $225.6 million in 2025.
  • Business Quant data shows Revenue for ORGO at $225.6 million in Q4 2025, $150.9 million in Q3 2025, and $101.0 million in Q2 2025.